Literature DB >> 16631587

An inducible mouse model for PAX2-dependent glomerular disease: insights into a complex pathogenesis.

Kay-Dietrich Wagner1, Nicole Wagner, Jian-Kan Guo, Marlies Elger, Margaret J Dallman, Laurence Bugeon, Andreas Schedl.   

Abstract

Pax2 is a transcription factor with important functions during kidney development . Ectopic expression of Pax2 in podocytes has been reported in various glomerular diseases , but the functional relevance remains unknown. We developed an inducible mouse model that allows activation of Pax2 specifically in podocytes. Persistent expression of Pax2 did not interfere with the initial differentiation of podocytes, but mice ectopically expressing PAX2 developed end-stage renal failure soon after birth. Similarly, activation of PAX2 in healthy adult animals resulted in renal disease within 3 weeks after podocyte-specific induction of a deleter Cre. PAX2 activation caused repression of the podocyte key regulator molecule Wt1 and consequently a dramatic reduction of nephrin expression. Recruitment of the groucho-related protein TLE4 may be involved in converting Pax2 into a transcriptional repressor of Wt1. Finally, treatment of mice with an angiotensin-converting enzyme (ACE) inhibitor normalized renal function and induced upregulation of the important structural molecule nephrin via a Wt1-independent pathway. Our data demonstrate the functional significance of PAX2 reexpression in mature podocytes for the development of glomerular diseases and suggest that reactivation of PAX genes in terminally differentiated cells leads to a more dedifferentiated phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631587     DOI: 10.1016/j.cub.2006.02.072

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  15 in total

1.  Mutations in PAX2 associate with adult-onset FSGS.

Authors:  Moumita Barua; Emilia Stellacci; Lorenzo Stella; Astrid Weins; Giulio Genovese; Valentina Muto; Viviana Caputo; Hakan R Toka; Victoria T Charoonratana; Marco Tartaglia; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2014-03-27       Impact factor: 10.121

Review 2.  Nephron number, hypertension, and CKD: physiological and genetic insight from humans and animal models.

Authors:  Xuexiang Wang; Michael R Garrett
Journal:  Physiol Genomics       Date:  2017-01-27       Impact factor: 3.107

Review 3.  PAX2 in human kidney malformations and disease.

Authors:  Lyndsay A Harshman; Patrick D Brophy
Journal:  Pediatr Nephrol       Date:  2011-12-03       Impact factor: 3.714

4.  A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue.

Authors:  Jeffrey B Hodgin; Alain C Borczuk; Samih H Nasr; Glen S Markowitz; Viji Nair; Sebastian Martini; Felix Eichinger; Courtenay Vining; Celine C Berthier; Matthias Kretzler; Vivette D D'Agati
Journal:  Am J Pathol       Date:  2010-09-16       Impact factor: 4.307

5.  Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development.

Authors:  Kimberly J Reidy; Guillermo Villegas; Jason Teichman; Delma Veron; Wa Shen; Juan Jimenez; David Thomas; Alda Tufro
Journal:  Development       Date:  2009-12       Impact factor: 6.868

Review 6.  Transcriptional regulation of podocyte disease.

Authors:  Sumant S Chugh
Journal:  Transl Res       Date:  2007-05       Impact factor: 7.012

7.  Renin-angiotensin axis blockade reduces proteinuria in presymptomatic patients with familial FSGS.

Authors:  Lawrence Copelovitch; Marta Guttenberg; Martin R Pollak; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2007-05-25       Impact factor: 3.714

8.  Advances in the biology and genetics of the podocytopathies: implications for diagnosis and therapy.

Authors:  Laura Barisoni; H William Schnaper; Jeffrey B Kopp
Journal:  Arch Pathol Lab Med       Date:  2009-02       Impact factor: 5.534

9.  SUMOylated SoxE factors recruit Grg4 and function as transcriptional repressors in the neural crest.

Authors:  Pei-Chih Lee; Kimberly M Taylor-Jaffe; Kara M Nordin; Maneeshi S Prasad; Rachel M Lander; Carole LaBonne
Journal:  J Cell Biol       Date:  2012-08-27       Impact factor: 10.539

10.  CMIP interacts with WT1 and targets it on the proteasome degradation pathway.

Authors:  Shao-Yu Zhang; Qingfeng Fan; Anissa Moktefi; Virginie Ory; Vincent Audard; Andre Pawlak; Mario Ollero; Dil Sahali; Carole Henique
Journal:  Clin Transl Med       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.